PKI-402 is a potent pan-PI3K/mTOR dual inhibitor used for targeting PI3Kα/β/γ/δ and mTOR (IC50 = 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively), including PI3Kα mutants E545K and H1047R; it inhibits the growth of human tumor cell lines (IC50 = 6–349 nM); suppresses phosphorylation of PI3K and mTOR downstream effectors such as Akt (T308 and S473), p70S6K, 4EBP1, PRAS40 (T246), eNOS (S1177), and GSK3α/β (S21/S9); induces apoptosis (as indicated by cleaved PARP) in PI3Kα-mutant (E545K) and Her2-overexpressing breast cancer cells (e.g., MDA-MB-361); and demonstrates significant antitumor activity in vivo against MDA-MB-361, A549, and U87MG xenograft models.